Literature DB >> 10923916

Gene expression of vascular endothelial growth factor in giant cell tumors of bone.

M H Zheng1, J Xu, P Robbins, N Pavlos, S Wysocki, S M Kumta, D J Wood, J M Papadimitriou.   

Abstract

The production of vascular endothelial growth factors (VEGF), a major cause of neoangiogenesis, is a prerequisite for tumor growth and invasion. VEGF have also been shown to be important for the formation of osteoclasts. Because giant cell tumors of bone (GCT) are frequently hypervascular and have the ability to recruit macrophages and multinucleated osteoclast-like giant cells, we evaluated the levels of VEGF gene transcript in several of these tumors using Northern blot analyses, semiquantitative reverse transcription polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), and immunohistochemistry. Our results showed that three major isoforms of VEGF (121, 165, and 189) were expressed in all cases of GCT investigated, with isoform 121 transcripts the most abundant. By both FISH and immunohistochemistry, we have shown that VEGF was present in spindle-shaped stromal-like tumor cells, round macrophage-like cells, and osteoclast-like multinucleate giant cells. Moreover, we have shown that the levels of VEGF gene expression but not microvessel density correlated with Enneking's clinical stage of GCT. There were higher levels of VEGF gene expression in stage III GCT than in stage I/II GCT (P < .0357). In conclusion, our results indicate that overexpression of VEGF may be associated with the advanced stage of the neoplasm.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923916     DOI: 10.1053/hupa.2000.8441

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

Review 1.  Giant cell tumor of bone.

Authors:  Alan W Yasko
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

2.  Single-cell RNA sequencing reveals differential expression of EGFL7 and VEGF in giant-cell tumor of bone and osteosarcoma.

Authors:  Mesalie Feleke; Wenyu Feng; Dezhi Song; Hengyuan Li; Emel Rothzerg; Qingjun Wei; Sulev Kõks; David Wood; Yun Liu; Jiake Xu
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-13

3.  Matrix metalloproteinase 1: role in sarcoma biology.

Authors:  Muhammad Umar Jawad; Nandor Garamszegi; Susanna P Garamszegi; Mayrin Correa-Medina; Juan A Diez; Rong Wen; Sean P Scully
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

4.  Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone.

Authors:  Yoshihiro Matsumoto; Yuko Okada; Jun-Ichi Fukushi; Satoshi Kamura; Toshifumi Fujiwara; Keiichiro Iida; Mihoko Koga; Shuichi Matsuda; Katsumi Harimaya; Akio Sakamoto; Yukihide Iwamoto
Journal:  J Orthop Surg Res       Date:  2010-11-09       Impact factor: 2.359

5.  Hypoxia markers in human osteosarcoma: an exploratory study.

Authors:  Hiroo Mizobuchi; José Manuel García-Castellano; Shaji Philip; John H Healey; Richard Gorlick
Journal:  Clin Orthop Relat Res       Date:  2008-06-05       Impact factor: 4.176

Review 6.  Giant cell tumor of the uterus: case report and response to chemotherapy.

Authors:  Keith M Skubitz; J Carlos Manivel
Journal:  BMC Cancer       Date:  2007-03-14       Impact factor: 4.430

7.  Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone.

Authors:  Peter Balla; Mate Elod Maros; Gabor Barna; Imre Antal; Gergo Papp; Zoltan Sapi; Nicholas Anthony Athanasou; Maria Serena Benassi; Pierro Picci; Tibor Krenacs
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

Review 8.  The Central Role of Biometals Maintains Oxidative Balance in the Context of Metabolic and Neurodegenerative Disorders.

Authors:  Michal Pokusa; Alžbeta Kráľová Trančíková
Journal:  Oxid Med Cell Longev       Date:  2017-07-02       Impact factor: 6.543

9.  Plasma metabolite profiling reveals potential biomarkers of giant cell tumor of bone by using NMR-based metabolic profiles: A cross-sectional study.

Authors:  Wei Wang; Xilin Liu; Juan Wu; Xia Kang; Qingyun Xie; Jun Sheng; Wei Xu; Da Liu; Wei Zheng
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

10.  Overexpression of hypoxia-inducible factor-1α and vascular endothelial growth factor in sacral giant cell tumors and the correlation with tumor microvessel density.

Authors:  Shaofeng Fu; Rui Bai; Zhenqun Zhao; Zhifeng Zhang; Gang Zhang; Yuxin Wang; Yong Wang; Dianming Jiang; Dezhi Zhu
Journal:  Exp Ther Med       Date:  2014-09-17       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.